The markets for MediKane products are vast, global, and growing.
The number of cases and the prevalence of high blood sugar levels have been steadily increasing over many decades. Research by the International Diabetes Federation (IDF) 2021 shows that in 2000 there were 151 million adults with diabetes. In 2021, 537 million adults (20-79 years) are living with diabetes worldwide – 1 in 10.
Factors driving this dramatic rise include lifestyle, food choices, excessive weight gain and obesity.
Diabetes is the epidemic of the 21st century and the biggest challenge confronting Australia’s health system ('Diabetes in Australia' – Diabetes Australia)
- 280 Australians develop diabetes every day. That’s one person every five minutes.
- Around 1.8 million Australians have diabetes. This includes all types of diagnosed diabetes (1.3 million known and registered) as well as silent, undiagnosed type 2 diabetes (up to 500,000 estimated) (Link to Source).
- More than 120,000 Australians have developed diabetes in the past year.
- For every person diagnosed with diabetes there is usually a family member or carer who also ‘lives with diabetes’ every day in a support role. This means that an estimated 2.4 million Australians are affected by diabetes every day.
- Total annual cost impact of diabetes in Australia estimated at $14.6 billion (Link to Source).
High BSLs is the leading cause of preventable blindness in Australia.
There are more than 4,000 amputations every year in Australia due to diabetes complications.
There are no blockbuster drugs on the horizon, so treatment focuses on managing the blood sugar levels over the lifetime of those patients.
Pharmaceuticals are not yet a solution:
- They cannot be taken by all patients (e.g. some medications cannot be used by patients with chronic kidney disease).
- Their efficacy deteriorates over time due to habituation.
- Many drugs can cause serious negative side effects.
- Interventions become life critical when medicines and insulin injections cannot manage blood sugar levels.
- Taking insulin is invasive. Insulin dosing is by injection as stomach acid will destroy it if taken orally.
Clinical trials have shown that NutriKane D has a positive impact on high BSLs. Using NutriKane D improves the efficacy of interventions and progression to secondary or tertiary stages becomes delayed or even prevented.
As a food product, NutriKane D has been approved for claims by the Food Standards Australia New Zealand (FSANZ) relating to the management of blood sugar levels.
MediKane’s key markets are the USA, China and India. Combined, these markets represent 50% of the potential global market.
The accessible market for NutriKane D is defined as people living with high BSLs, using oral drugs for blood glucose control, looking for natural medications, can afford the product and who can access the product (i.e. good distribution networks and retail outlets); this represents approximately 65 million people worldwide.
Of those 65 million people, MediKane is focused on the accessible markets in Australia and the USA in the short term, which together total 5.7 million people.
In Australia, MediKane has been working closely with the ADEA to increase the awareness of the product and its efficacy. ADEA’s educators are champions of NutriKane D and are increasingly recommending NutriKane D to people with high BSLs for superior, effective, all-natural management of the disease.
The USA is the most significant market for all MediKane products. The market in the USA is lower than in both India and China, however due to superior healthcare services, superior infrastructure, ease of communicating with consumers and high average wealth, the USA is MediKane’s key market.
MediKane has established a base office in the USA. Michael Goldman ex Diabetes Australia, is a Territory Manager for MediKane, based in the USA.